Jefferies Group's APLS Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 8,718 shares of Apellis Pharmaceuticals, Inc. (APLS) worth $218,997, representing 0.00% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in APLS, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 292,850 shares. Largest reduction occurred in Q3 2025, reducing 326,650 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Apellis Pharmaceuticals (APLS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Apellis Pharmaceuticals (APLS) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -242,837 | Reduce 96.53% | 8,718 | $25.12 |
| Q3 2025 | -326,650 | Reduce 56.49% | 251,555 | $22.63 |
| Q2 2025 | -21,050 | Reduce 3.51% | 578,205 | $17.31 |
| Q1 2025 | +257,894 | Add 75.55% | 599,255 | $21.87 |
| Q4 2024 | +292,850 | Add 603.68% | 341,361 | $31.91 |
| Q3 2024 | +47,875 | Add 7527.52% | 48,511 | $28.84 |
| Q1 2024 | -21,908 | Reduce 97.18% | 636 | $58.78 |
| Q4 2023 | +18,236 | Add 423.31% | 22,544 | $59.86 |
| Q3 2023 | -12,892 | Reduce 74.95% | 4,308 | $38.04 |
| Q2 2023 | +14,725 | Add 594.95% | 17,200 | $91.10 |
| Q1 2023 | +2,475 | New Buy | 2,475 | $65.96 |
Jefferies Group's Apellis Pharmaceuticals Investment FAQs
Jefferies Group first purchased Apellis Pharmaceuticals, Inc. (APLS) in Q1 2023, acquiring 2,475 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Apellis Pharmaceuticals, Inc. (APLS) for 12 quarters since Q1 2023.
Jefferies Group's largest addition to Apellis Pharmaceuticals, Inc. (APLS) was in Q4 2024, adding 341,361 shares worth $10.89 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 8,718 shares of Apellis Pharmaceuticals, Inc. (APLS), valued at approximately $218,997.
As of the Q4 2025 filing, Apellis Pharmaceuticals, Inc. (APLS) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Apellis Pharmaceuticals, Inc. (APLS) was 599,255 shares, as reported at the end of Q1 2025.